Overview
AnaptysBio Q3 collaboration revenue rises significantly due to GSK milestone achievements
Company plans to separate biopharma operations from royalty assets by YE 2026
AnaptysBio reports Q3 net income, contrasting with a loss in the prior year
Outlook
AnaptysBio plans to separate biopharma operations from royalty assets by YE 2026
Company expects $75 mln milestone from GSK's Jemperli sales in Q4 2025
AnaptysBio expects annualized Jemperli royalties of >$390 mln before 2031
Result Drivers
GSK MILESTONE - Collaboration revenue boosted by $50 mln milestone from GSK's Jemperli sales exceeding $750 mln
BIOPHARMA SEPARATION - Intent to separate biopharma operations from royalty assets by YE 2026 to unlock value
ROSNILIMAB DATA - Positive Phase 2b data for rosnilimab in rheumatoid arthritis highlighted at ACR Convergence 2025
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Collaboration Revenue | $76.32 mln | ||
Q3 Net Income | $15.11 mln | ||
Q3 Income From Operations | $34.70 mln | ||
Q3 Operating Expenses | $41.61 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for AnaptysBio Inc is $62.00, about 41.9% above its November 3 closing price of $36.04
Press Release: ID:nGNX5Gv9LF
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)